在最初观察到的低肿瘤负荷滤泡性淋巴瘤中,低总代谢肿瘤体积独立预测首次治疗的时间更长。

IF 3.3 4区 医学 Q2 HEMATOLOGY
Pablo Mozas, Sebastian Casanueva-Eliceiry, Andrea Rivero, Ángel Serna, Marc Simó, Sonia Rodríguez, Alfredo Rivas-Delgado, Ferran Nadeu, Juan Gonzalo Correa, Juan Antonio Piñeyroa, Amanda Isabel Pérez-Valencia, Katia Guinetti-Ortiz, Marta Gómez-Hernando, Eva Giné, Julio Delgado, Neus Villamor, Elías Campo, Laura Magnano, Pau Abrisqueta, Xavier Setoain, Armando López-Guillermo
{"title":"在最初观察到的低肿瘤负荷滤泡性淋巴瘤中,低总代谢肿瘤体积独立预测首次治疗的时间更长。","authors":"Pablo Mozas,&nbsp;Sebastian Casanueva-Eliceiry,&nbsp;Andrea Rivero,&nbsp;Ángel Serna,&nbsp;Marc Simó,&nbsp;Sonia Rodríguez,&nbsp;Alfredo Rivas-Delgado,&nbsp;Ferran Nadeu,&nbsp;Juan Gonzalo Correa,&nbsp;Juan Antonio Piñeyroa,&nbsp;Amanda Isabel Pérez-Valencia,&nbsp;Katia Guinetti-Ortiz,&nbsp;Marta Gómez-Hernando,&nbsp;Eva Giné,&nbsp;Julio Delgado,&nbsp;Neus Villamor,&nbsp;Elías Campo,&nbsp;Laura Magnano,&nbsp;Pau Abrisqueta,&nbsp;Xavier Setoain,&nbsp;Armando López-Guillermo","doi":"10.1002/hon.3235","DOIUrl":null,"url":null,"abstract":"<p>Watchful waiting is an acceptable management strategy for advanced-stage, low tumor burden (LTB) patients with follicular lymphoma (FL). However, the prediction of how long this treatment-free observation period will last remains imperfect. We explored whether total metabolic tumor volume (TMTV) and other positron emission tomography parameters were predictive of time to first treatment (TTFT). We analyzed 97 grade 1–3A advanced-stage LTB FL patients and found that a high TMTV was associated with other tumor burden features at diagnosis. Patients with a TMTV above our established cutoff of 50 mL had a significantly shorter median duration of observation (2.6 vs. 8.8 years; <i>p</i> = 0.001). At 5 years, 77% of patients with a high TMTV and 46% of patients with a low TMTV required treatment. In the multivariable analysis, a high TMTV was the only independent factor predicting TTFT (hazard ratio = 2.09; <i>p</i> = 0.017). Overall, TMTV is a strong predictor of the duration of observation in LTB FL patients. Upon validation of our cutoff in external series and standardization of the methodology, the TMTV could become an additional factor to consider deferring or initiating treatment in otherwise LTB patients.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":null,"pages":null},"PeriodicalIF":3.3000,"publicationDate":"2023-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3235","citationCount":"0","resultStr":"{\"title\":\"A low total metabolic tumor volume independently predicts for a longer time to first treatment in initially observed, low tumor burden follicular lymphoma\",\"authors\":\"Pablo Mozas,&nbsp;Sebastian Casanueva-Eliceiry,&nbsp;Andrea Rivero,&nbsp;Ángel Serna,&nbsp;Marc Simó,&nbsp;Sonia Rodríguez,&nbsp;Alfredo Rivas-Delgado,&nbsp;Ferran Nadeu,&nbsp;Juan Gonzalo Correa,&nbsp;Juan Antonio Piñeyroa,&nbsp;Amanda Isabel Pérez-Valencia,&nbsp;Katia Guinetti-Ortiz,&nbsp;Marta Gómez-Hernando,&nbsp;Eva Giné,&nbsp;Julio Delgado,&nbsp;Neus Villamor,&nbsp;Elías Campo,&nbsp;Laura Magnano,&nbsp;Pau Abrisqueta,&nbsp;Xavier Setoain,&nbsp;Armando López-Guillermo\",\"doi\":\"10.1002/hon.3235\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Watchful waiting is an acceptable management strategy for advanced-stage, low tumor burden (LTB) patients with follicular lymphoma (FL). However, the prediction of how long this treatment-free observation period will last remains imperfect. We explored whether total metabolic tumor volume (TMTV) and other positron emission tomography parameters were predictive of time to first treatment (TTFT). We analyzed 97 grade 1–3A advanced-stage LTB FL patients and found that a high TMTV was associated with other tumor burden features at diagnosis. Patients with a TMTV above our established cutoff of 50 mL had a significantly shorter median duration of observation (2.6 vs. 8.8 years; <i>p</i> = 0.001). At 5 years, 77% of patients with a high TMTV and 46% of patients with a low TMTV required treatment. In the multivariable analysis, a high TMTV was the only independent factor predicting TTFT (hazard ratio = 2.09; <i>p</i> = 0.017). Overall, TMTV is a strong predictor of the duration of observation in LTB FL patients. Upon validation of our cutoff in external series and standardization of the methodology, the TMTV could become an additional factor to consider deferring or initiating treatment in otherwise LTB patients.</p>\",\"PeriodicalId\":12882,\"journal\":{\"name\":\"Hematological Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2023-11-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3235\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematological Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hon.3235\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.3235","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

对于晚期、低肿瘤负担(LTB)的滤泡性淋巴瘤(FL)患者,观察等待是一种可接受的管理策略。然而,对这种无治疗观察期将持续多久的预测仍然不完善。我们探讨了总代谢肿瘤体积(TMTV)和其他正电子发射断层扫描参数是否可以预测首次治疗时间(TTFT)。我们分析了97例1-3A级晚期LTB FL患者,发现高TMTV与诊断时的其他肿瘤负荷特征有关。TMTV高于我们设定的50mL临界值的患者的中位观察时间明显更短(2.6年对8.8年;p=0.001)。在5年时,77%的TMTV高患者和46%的TMTV低患者需要治疗。在多变量分析中,高TMTV是预测TTFT的唯一独立因素(危险比=2.09;p=0.017)。总体而言,TMTV是LTB-FL患者观察持续时间的有力预测因素。在验证了我们在外部系列中的截止值和方法的标准化后,TMTV可能会成为考虑推迟或启动LTB患者治疗的额外因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

A low total metabolic tumor volume independently predicts for a longer time to first treatment in initially observed, low tumor burden follicular lymphoma

A low total metabolic tumor volume independently predicts for a longer time to first treatment in initially observed, low tumor burden follicular lymphoma

Watchful waiting is an acceptable management strategy for advanced-stage, low tumor burden (LTB) patients with follicular lymphoma (FL). However, the prediction of how long this treatment-free observation period will last remains imperfect. We explored whether total metabolic tumor volume (TMTV) and other positron emission tomography parameters were predictive of time to first treatment (TTFT). We analyzed 97 grade 1–3A advanced-stage LTB FL patients and found that a high TMTV was associated with other tumor burden features at diagnosis. Patients with a TMTV above our established cutoff of 50 mL had a significantly shorter median duration of observation (2.6 vs. 8.8 years; p = 0.001). At 5 years, 77% of patients with a high TMTV and 46% of patients with a low TMTV required treatment. In the multivariable analysis, a high TMTV was the only independent factor predicting TTFT (hazard ratio = 2.09; p = 0.017). Overall, TMTV is a strong predictor of the duration of observation in LTB FL patients. Upon validation of our cutoff in external series and standardization of the methodology, the TMTV could become an additional factor to consider deferring or initiating treatment in otherwise LTB patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Hematological Oncology
Hematological Oncology 医学-血液学
CiteScore
4.20
自引率
6.10%
发文量
147
审稿时长
>12 weeks
期刊介绍: Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信